GlassScriptPhysician profile
Laura L Fitzpatrick
NPI 1245270297
$1,391.76
in general payments reported to CMS, 2019-2025
17 companies · $371 in 2025
The $371 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $56.80 · 2021: $149 · 2022: $94.78 · 2023: $250 · 2024: $306 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $927.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $208.36 | 2020-2025 | Freestyle Libre 3 |
| Amgen INC. | $196.83 | 2019-2025 | Evenity, Prolia, Tepezza |
| Insulet Corporation | $179.04 | 2019-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $158.85 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $139.57 | 2019-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $138.08 | 2021-2025 | Minimed 780g |
| Tolmar, INC. | $67.18 | 2024-2025 | Jatenzo |
| Abbvie INC. | $61.45 | 2023-2024 | |
| Lilly USA, LLC | $50.75 | 2020-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $34.47 | 2022-2023 | Gvoke Hypopen |
| Novo Nordisk INC | $31.51 | 2019-2024 | Ozempic |
| Astellas Pharma US INC | $30.40 | 2025 | Veozah |
| Beta Bionics, INC. | $23.99 | 2024 | Ilet Bionic Pancreas |
| Novartis Pharmaceuticals Corporation | $21.09 | 2025 | |
| Ascendis Pharma Endocrinology INC | $19.40 | 2025 | Yorvipath |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $18.50 | 2019 | |
| Vistapharm, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Fitzpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.